Switch theme
Sign up to access all valuation multiples
Nanjing King-Friend Biochemical Pharmaceutical Co Ltd is a China-based company engaged in the research and development, import and export of medicines and health products. The main products of the company are Heparin sodium and low molecular weight heparin. Geographically, the business activities are carried out through China and it exports the product mainly to the European and American countries.
2000
n/a
LTM Revenue $608M
LTM EBITDA $164M
$2.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Nanjing King-Friend has a last 12-month revenue of $608M and a last 12-month EBITDA of $164M.
In the most recent fiscal year, Nanjing King-Friend achieved revenue of $542M and an EBITDA of -$8.2M.
Nanjing King-Friend expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Nanjing King-Friend valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $542M | $571M | XXX | XXX | XXX |
| Gross Profit | $288M | $268M | XXX | XXX | XXX |
| Gross Margin | 53% | 47% | XXX | XXX | XXX |
| EBITDA | -$8.2M | $153M | XXX | XXX | XXX |
| EBITDA Margin | -2% | 27% | XXX | XXX | XXX |
| Net Profit | $146M | $150M | XXX | XXX | XXX |
| Net Margin | 27% | 26% | XXX | XXX | XXX |
| Net Debt | $191M | $215M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Nanjing King-Friend's stock price is CNY 12 (or $2).
Nanjing King-Friend has current market cap of CNY 19.0B (or $2.6B), and EV of CNY 19.3B (or $2.7B).
See Nanjing King-Friend trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.7B | $2.6B | XXX | XXX | XXX | XXX | $0.10 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Nanjing King-Friend has market cap of $2.6B and EV of $2.7B.
Nanjing King-Friend's trades at 4.4x LTM EV/Revenue multiple, and 16.2x LTM EBITDA.
Analysts estimate Nanjing King-Friend's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Nanjing King-Friend and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.7B | XXX | XXX | XXX |
| EV/Revenue | 4.7x | XXX | XXX | XXX |
| EV/EBITDA | 17.4x | XXX | XXX | XXX |
| P/E | 21.1x | XXX | XXX | XXX |
| P/E/Growth | 0.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpNanjing King-Friend's NTM/LTM revenue growth is 21%
Nanjing King-Friend's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Nanjing King-Friend's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Nanjing King-Friend's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Nanjing King-Friend and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -1962% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 48% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 11% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 9% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 24% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nanjing King-Friend acquired XXX companies to date.
Last acquisition by Nanjing King-Friend was XXXXXXXX, XXXXX XXXXX XXXXXX . Nanjing King-Friend acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Nanjing King-Friend founded? | Nanjing King-Friend was founded in 2000. |
| Where is Nanjing King-Friend headquartered? | Nanjing King-Friend is headquartered in China. |
| Is Nanjing King-Friend publicy listed? | Yes, Nanjing King-Friend is a public company listed on SHG. |
| What is the stock symbol of Nanjing King-Friend? | Nanjing King-Friend trades under 603707 ticker. |
| When did Nanjing King-Friend go public? | Nanjing King-Friend went public in 2017. |
| Who are competitors of Nanjing King-Friend? | Similar companies to Nanjing King-Friend include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Nanjing King-Friend? | Nanjing King-Friend's current market cap is $2.6B |
| What is the current revenue of Nanjing King-Friend? | Nanjing King-Friend's last 12-month revenue is $608M. |
| What is the current EBITDA of Nanjing King-Friend? | Nanjing King-Friend's last 12-month EBITDA is $164M. |
| What is the current EV/Revenue multiple of Nanjing King-Friend? | Current revenue multiple of Nanjing King-Friend is 4.4x. |
| What is the current EV/EBITDA multiple of Nanjing King-Friend? | Current EBITDA multiple of Nanjing King-Friend is 16.2x. |
| What is the current revenue growth of Nanjing King-Friend? | Nanjing King-Friend revenue growth between 2023 and 2024 was 5%. |
| Is Nanjing King-Friend profitable? | Yes, Nanjing King-Friend is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
